Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531274 | PMC |
| http://dx.doi.org/10.1016/j.mayocp.2021.10.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Safe and Broad-spectrum SARS-CoV-2 mRNA Vaccine with a New Delivery System for In-situ Expression.
Virol Sin
September 2025
State Key Laboratory of Virology and Biosafety, RNA Institute, College of Life Sciences and Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, 430072, China; Institute for Vaccine Research at Animal Bio-safety Level Ⅲ Laboratory, Wuhan University, Wuhan, 430071, China.
Since the outbreak of SARS-CoV-2 in late 2019, the cumulative number of confirmed cases worldwide has surpassed 778 million, and the number of deaths has exceeded 7 million, posing a significant threat to human life and health while inflicting enormous losses on the global economy. At the stage where sequential immunization is recommended, there is a pressing demand for mRNA vaccines that can be rapidly adapted to new sequences, are easy to industrialize, and exhibit high safety and effectiveness. We developed a lipid nanoparticle (LNP) system, designated as WNP, which facilitates essentially in situ expression at the injection site and results in lower levels of pro-inflammatory factors in the liver, thus enhancing its safety compared to liver-targeted alternatives.
View Article and Find Full Text PDFQuantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada.
Autoimmunity
December 2025
Medicinal Genomics, Beverly, MA, USA.
For some of the COVID-19 vaccines, the drug substances released to market were manufactured differently than those used in clinical trials. Manufacturing nucleoside-modified mRNA (modRNA) for commercial COVID-19 vaccines relies on RNA polymerase transcription of a plasmid DNA template. Previous studies identified high levels of plasmid DNA in vials of modRNA vaccines, suggesting that the removal of residual DNA template is problematic.
View Article and Find Full Text PDFUnlabelled: The evolution of SARS-CoV-2 has resulted in antigenically distinct variants that challenge vaccine-induced immunity. The KP.2 monovalent mRNA vaccine was deployed in 2024 to address immune escape by emerging SARS-CoV-2 subvariants.
View Article and Find Full Text PDFA key goal of vaccinology is to train the immune system to combat current pathogens while simultaneously preparing it for future evolved variants. Understanding factors contributing to anticipatory breadth, wherein affinity maturation against an ancestral strain yields neutralization capacity against evolved variants, is therefore of great importance. Here, we investigated the mechanism of anticipatory breadth development in a public antibody family targeting the functionally restricted ACE2 binding site on SARS-CoV-2.
View Article and Find Full Text PDFCellular and humoral immunity following two AZD1222 and two booster vaccinations in hemodialysis patients.
J Microbiol Immunol Infect
August 2025
Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address:
Background: Dialysis patients are vulnerable to SARS-CoV-2 infection and subsequent complications. However, the vaccine-induced immunity, especially against new variants, following two AZD1222 and two booster doses in hemodialysis patients remain largely unknown.
Methods: In this observational cohort study, we monitored immune responses in 127 hemodialysis patients receiving the 3 and 4th vaccinations until three months after the 4th immunization.